دورية أكاديمية
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
| العنوان: | Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma |
|---|---|
| المؤلفون: | Richardson, Paul G, Jacobus, Susanna J, Weller, Edie A, Hassoun, Hani, Lonial, Sagar, Raje, Noopur S, Medvedova, Eva, McCarthy, Philip L, Libby, Edward N, Voorhees, Peter M, Orlowski, Robert Z, Anderson, Larry D, Zonder, Jeffrey A, Milner, Carter P, Gasparetto, Cristina, Agha, Mounzer E, Khan, Abdullah M, Hurd, David D, Gowin, Krisstina, Kamble, Rammurti T, Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Cornell, R Frank, Hashmi, Hamza, Campagnaro, Erica L, Andreescu, Astrid C, Gentile, Teresa, Liedtke, Michaela, Godby, Kelly N, Cohen, Adam D, Openshaw, Thomas H, Pasquini, Marcelo C, Giralt, Sergio A, Kaufman, Jonathan L, Yee, Andrew J, Scott, Emma, Torka, Pallawi, Foley, Amy, Fulciniti, Mariateresa, Hebert, Kyle, Samur, Mehmet K, Masone, Kelly, Maglio, Michelle E, Zeytoonjian, Andrea A, Nadeem, Omar, Schlossman, Robert L, Laubach, Jacob P, Paba-Prada, Claudia, Ghobrial, Irene M, Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Anderson, Kenneth C, Munshi, Nikhil C |
| المساهمون: | Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona |
| المصدر: | The New England journal of medicine ; 387 ; 2 ; 132 ; 147 ; United States |
| بيانات النشر: | Massachussetts Medical Society |
| سنة النشر: | 2022 |
| المجموعة: | The University of Arizona: UA Campus Repository |
| الوصف: | BACKGROUND In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. METHODS In this phase 3 trial, adults (18 to 65 years of age) with symptomatic myeloma received one cycle of RVD. We randomly assigned these patients, in a 1:1 ratio, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five additional RVD cycles (the RVD-alone group) or high-dose melphalan plus ASCT followed by two additional RVD cycles (the transplantation group). Both groups received lenalidomide until disease progression, unacceptable side effects, or both. The primary end point was progression-free survival. RESULTS Among 357 patients in the RVD-alone group and 365 in the transplantation group, at a median follow-up of 76.0 months, 328 events of disease progression or death occurred; the risk was 53% higher in the RVD-alone group than in the transplantation group (hazard ratio, 1.53; 95% confidence interval [CI], 1.23 to 1.91; P<0.001); median progression-free survival was 46.2 months and 67.5 months. The percentage of patients with a partial response or better was 95.0% in the RVD-alone group and 97.5% in the transplantation group (P=0.55); 42.0% and 46.8%, respectively, had a complete response or better (P=0.99). Treatment-related adverse events of grade 3 or higher occurred in 78.2% and 94.2%, respectively; 5-year survival was 79.2% and 80.7% (hazard ratio for death, 1.10; 95% CI, 0.73 to 1.65). CONCLUSIONS Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed. ; 6 month embargo; published online: 05 June 2022 ; This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1533-4406 |
| العلاقة: | Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., Orlowski, R. Z., Anderson, L. D., Jr., Zonder, J. A., Milner, C. P., Gasparetto, C., Agha, M. E., Khan, A. M., Hurd, D. D., Gowin, K., … Munshi, N. C. (2022). Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 387(2), 132–147.; http://hdl.handle.net/10150/665902Test; New England Journal of Medicine |
| DOI: | 10.1056/NEJMoa2204925 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa2204925Test http://hdl.handle.net/10150/665902Test |
| حقوق: | Copyright © 2022 Massachusetts Medical Society. ; http://rightsstatements.org/vocab/InC/1.0Test/ |
| رقم الانضمام: | edsbas.6A5B5E2F |
| قاعدة البيانات: | BASE |
| تدمد: | 15334406 |
|---|---|
| DOI: | 10.1056/NEJMoa2204925 |